Gut microbiome treatment-resistant schizophrenia - Nuala Murray explores the role of the gut microbiome in ...

An estimated one-quarter to one-third of people with schizophrenia have symptoms that don’t improve with traditional ...

Schizophrenia is a severe and debilitating psychiatric disorder that involves psychotic symptoms such as hallucinations and delusions, accompanied with regressive behaviour. Utilizing ...

The post Technion-led project for early schizophrenia diagnosis secures €8m EU grant appeared first on The Times of Israel.

The project focuses on improving early diagnosis and monitoring of schizophrenia – a chronic condition affecting approximately 1% of the global population (80 million people). Schizophrenia is one of ...

Atypical antipsychotic drugs have been shown to be more efficacious in treating cognitive disturbances of schizophrenia compared with typical antipsychotic drugs. Serotonin (5-hydroxytryptamine [5 ...

Boehringer Ingelheim is to collaborate with UK biotech Autifony Therapeutics to develop an early-stage schizophrenia drug and other compounds. Although central nervous system diseases are a focus ...

Bristol-Myers Squibb's $14 billion bet on buying Karuna Therapeutics looks set to pay off after it got FDA approval for the schizophrenia drug at the heart of the deal. The US regulator has ...

In the acute phase, a trial of 8-20 ECT treatments, in addition to continuing antipsychotics, may be indicated for catatonic schizophrenia, treatment-resistant schizophrenia, or severe depression ...

Risk factors for psychosis may include hallucinogen use, based on individuals with an ED visit involving hallucinogens being more likely to develop an SSD.

The petition includes a forensic psychiatrist’s evaluation of documents on Joseph Corcoran’s mental health spanning decades.

EQS-News: Newron Pharmaceuticals S.p.A. / Key word (s): Agreement Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian ...